Halper Sadeh Investigates Whether Ultralife Shareholders Get a Fair $16 Price From EnerSys

Halper Sadeh LLC is investigating Ultralife Corporation's proposed sale to EnerSys for $16.00 per share in cash, the investor rights law firm said in a Business Wire announcement on October 28, 2026. The inquiry concerns whether Ultralife and its board violated federal securities laws or breached fiduciary duties.

Halper Sadeh's Questions About the Ultralife Sale

Halper Sadeh said the investigation examines whether Ultralife and its directors failed to obtain the best possible price for shareholders, failed to run a fair sales process free of conflicts of interest, and failed to disclose all material information shareholders need to evaluate the transaction. The firm said insiders may stand to receive substantial financial benefits not available to ordinary shareholders, and that the proposed transaction may contain terms that could limit superior competing offers. On behalf of shareholders, Halper Sadeh may seek increased consideration, additional disclosures, or other relief and benefits. The firm said it would handle any matter on a contingent fee basis, with shareholders not responsible for out-of-pocket legal fees or expenses. Daniel Sadeh and Zachary Halper are the contacts named in the announcement.

EnerSys agreed to acquire Ultralife for $16 per share in cash, a 166% premium, valuing the deal at about $320 million, according to The future of trading. EnerSys expects $15–20 million in annual run-rate cost synergies within 18 months and expects the deal to be accretive to EPS within 18 months, the outlet reported.

Halper Sadeh's Case Docket and Recoveries

According to akta.pro company records, Halper Sadeh was founded in New York in 2015 as a specialized investor rights law firm with a contingency-fee model. The same records list recoveries including $20 million in In re Galena Biopharma, Inc., Securities Litigation (D. Or.) and $23.5 million in Thomas v. Magnachip Semiconductor Corp. (N.D. Cal.). The records describe a 2026 expansion of its active case docket across real estate, mortgage, automotive, pharmaceuticals and large-cap technology, and a 2025 launch of a free portfolio monitoring service that notifies clients of market losses potentially caused by corporate fraud and assists with claim form filings.

Earlier Halper Sadeh Investigations

Halper Sadeh announced on August 24, 2026 that it was investigating Werewolf Therapeutics, Beazer Homes USA, MarketAxess Holdings and CBIZ for potential securities law violations and fiduciary duty breaches, FinancialContent Business Page reported. On August 28, 2026, the firm said it was investigating four companies for possible securities law violations and fiduciary duty breaches, the same outlet reported. On September 8, 2026, it was investigating Bio-Techne's sale to Merck, Colony Bankcorp's merger with First Reliance, and Auddia's merger with Thramann for potential securities law violations, FinancialContent Business Page reported.

EnerSys Results Date

EnerSys will release its second quarter fiscal 2027 financial results after market close on November 11, 2026, and host a conference call on November 12, 2026, Stock Titan reported. The results cover the period ended October 4, 2026.